SG11201911937UA - Amorphous and crystalline forms of ido inhibitors - Google Patents
Amorphous and crystalline forms of ido inhibitorsInfo
- Publication number
- SG11201911937UA SG11201911937UA SG11201911937UA SG11201911937UA SG11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous
- crystalline forms
- ido inhibitors
- ido
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762527855P | 2017-06-30 | 2017-06-30 | |
PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | Amorphous and crystalline forms of ido inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911937UA true SG11201911937UA (en) | 2020-01-30 |
Family
ID=64742242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911937UA SG11201911937UA (en) | 2017-06-30 | 2018-06-29 | Amorphous and crystalline forms of ido inhibitors |
Country Status (13)
Country | Link |
---|---|
US (2) | US11236049B2 (en) |
EP (1) | EP3644993B1 (en) |
JP (1) | JP2020526520A (en) |
KR (1) | KR102630575B1 (en) |
CN (1) | CN111093651B (en) |
AU (1) | AU2018294314A1 (en) |
BR (1) | BR112019027259A2 (en) |
CA (1) | CA3066789A1 (en) |
EA (1) | EA202090119A1 (en) |
IL (1) | IL271601B1 (en) |
MX (2) | MX2019014885A (en) |
SG (1) | SG11201911937UA (en) |
WO (1) | WO2019006283A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
WO2019097406A1 (en) * | 2017-11-17 | 2019-05-23 | Telefonaktiebolaget L M Ericsson (Publ) | Signaling ta-offset in nr |
CN110357813A (en) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application |
WO2020000236A1 (en) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | Crystal form of (r)-n-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl) propionamide |
US20240122857A1 (en) * | 2019-09-11 | 2024-04-18 | Bristol-Myers Squibb Company | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors |
WO2021108288A1 (en) * | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
AR120935A1 (en) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | AMIDE DERIVATIVES AND USES THEREOF |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
ES2591281T3 (en) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Combination therapies that employ GITR binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
SI2376535T1 (en) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
LT3023438T (en) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
ES2722300T3 (en) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Antibodies that preferentially bind to extracellular domain 4 of CSF1R and its use |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
BR112012022046A2 (en) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | "antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody". |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
KR101527300B1 (en) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb binding molecules |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
LT2699264T (en) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
KR101981873B1 (en) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
CN104159921B (en) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | Antibody for people CSF-1R and application thereof |
KR20140127855A (en) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Compositions and methods for using csf1r inhibitors |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
UY36390A (en) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AR102537A1 (en) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | IMMUNOMODULATING AGENTS |
US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
-
2018
- 2018-06-29 BR BR112019027259-3A patent/BR112019027259A2/en unknown
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/en active IP Right Grant
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 MX MX2019014885A patent/MX2019014885A/en unknown
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en active Application Filing
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 JP JP2020500206A patent/JP2020526520A/en active Pending
- 2018-06-29 IL IL271601A patent/IL271601B1/en unknown
- 2018-06-29 EA EA202090119A patent/EA202090119A1/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314A1/en active Pending
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/en active Active
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/en unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US20220169615A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102630575B1 (en) | 2024-01-29 |
US20220169615A1 (en) | 2022-06-02 |
CN111093651A (en) | 2020-05-01 |
WO2019006283A1 (en) | 2019-01-03 |
EP3644993B1 (en) | 2023-08-02 |
KR20200020916A (en) | 2020-02-26 |
EA202090119A1 (en) | 2020-04-21 |
CA3066789A1 (en) | 2019-01-03 |
CN111093651B (en) | 2023-06-06 |
EP3644993A1 (en) | 2020-05-06 |
EP3644993A4 (en) | 2021-03-10 |
AU2018294314A1 (en) | 2020-02-06 |
MX2019014885A (en) | 2020-02-13 |
BR112019027259A2 (en) | 2020-07-14 |
MX2021015656A (en) | 2022-02-03 |
US11236049B2 (en) | 2022-02-01 |
JP2020526520A (en) | 2020-08-31 |
US20200115342A1 (en) | 2020-04-16 |
IL271601A (en) | 2020-02-27 |
IL271601B1 (en) | 2024-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271601A (en) | Amorphous and crystalline forms of IDO inhibitors | |
HK1259232A1 (en) | Substituted inhibitors of menin-mll and methods of use | |
EP3684361A4 (en) | Substituted inhibitors of menin-mll and methods of use | |
IL267291B (en) | Ectonucleotidase inhibitors and methods of use thereof | |
PL3700902T3 (en) | Inhibitors of trpc6 | |
IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
IL282552A (en) | Crystalline forms of mnk inhibitors | |
HK1257171A1 (en) | Inhibitors of alk and srpk and methods of use | |
GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
ZA201904460B (en) | Inhibitors of nhe-mediated antiport | |
PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
IL251197A0 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
LT3327012T (en) | Crystalline forms of bilastine and preparation methods thereof | |
IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
PL3348546T3 (en) | Crystalline form of androgen receptor inhibitor and preparation method thereof | |
IL274758A (en) | Crystalline polymorphs of pracinostat and pracinostat salts | |
IL270937A (en) | Crystalline forms of seletalisib | |
HK1251560A1 (en) | Crystals of thiadiazole derivative dpp-iv inhibitors and uses thereof | |
GB201612717D0 (en) | Amorphous and crystaline forms of tadalfil | |
HK1244006A1 (en) | Crystalline forms of parp inhibitors | |
EP3565814A4 (en) | Process and crystalline forms of lumacaftor | |
EP3837356A4 (en) | Amorphous and crystalline forms of valbenazine salt | |
EP3102223A4 (en) | Crystalline and amorphous forms of a beta-arrestin effector |